Exicure Inc. is a biotechnology company focused on developing innovative therapies based on its proprietary SNA technology, which utilizes programmable RNA to target and modulate gene expression in various diseases
The company's primary efforts are aimed at treating genetic disorders and cancers by delivering therapeutic agents that can precisely interact with specific RNA molecules. Through advancing its scientific research and clinical development, Exicure aims to address unmet medical needs and improve treatment outcomes for patients.
GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.
Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. (“GPCR Therapeutics”) on December 24, 2024, aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, and the technology transfer and collaborative research on GPCR Therapeutics’ ongoing drug development pipelines. Through this acquisition, Exicure plans to secure key technical personnel by purchasing all shares of GPCR USA held by GPCR Therapeutics. Following this, Exicure intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, which is currently in Phase 2 clinical trials with the FDA, along with its related patents and intellectual property (IP). By acquiring excellent research personnel and clinical pipelines, Exicure aims to advance as a clinical-stage biotech company. GPCR Therapeutics plans to successfully finalize ongoing clinical trials involving stem cell mobilizers (SCM) targeting multiple myeloma patients and prepare for clinical studies related to acute myeloid leukemia (AML). The market size for the ongoing Phase 2 trials is estimated to be around $1 billion to $2 billion annually.
Exicure, Inc. (Nasdaq: XCUR, the "Company") has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value.
Shares of low-float micro-cap stock Exicure are rocketing higher in Wednesday's after-hours session after the company announced that it received an extension from the Nasdaq Hearings Panel.
